国内外医药产业创新体系对比分析  

Comparative Analysis of Domestic and Foreign Pharmaceutical Industry Innovation Systems

作　　者：甘春丽[1] 穆祯 孙丽平 王立波[1] 李畅 杨春娟[1] Gan Chunli;Mu Zhen;Sun Liping;Wang Libo;Li Chang;Yang Chunjuan(School of Pharmacy,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学药学院,哈尔滨150081

出　　处：《药学教育》2021年第1期48-53,共6页Pharmaceutical Education

基　　金：黑龙江省高等教育学会高等教育科学研究“十三五”规划课题,编号16Q070;黑龙江省规划办重点项目“产教结合培养药学创新人才的研究与实践”,编号GBB1317072。

摘　　要：新药研发的成本不断提高,开发难度不断加大,开发周期不断增长,诸多不可控风险导致新药研发在经历近十年的快速发展后进入瓶颈期。制药公司应如何突破瓶颈期,将新药研发风险降到最低,与是否拥有一个好的产业创新体系密不可分。分析制药公司采用的创新战略,比较国内外医药产业创新体系的优缺点,参照国外医药产业发展形势,提出建立和完善我国医药产业创新体系的建议。As the cost of new drug R&D continues to increase,the difficulty of development continues to increase,the development cycle continues to grow,and many uncontrollable risks lead to the bottleneck of new drug R&D after nearly a decade of rapid development.How pharmaceutical companies should break through the bottleneck period and minimize the risk of new drug development is closely related to whether they have a good industrial innovation system.This paper analyzes the innovation strategy adopted by pharmaceutical companies,compares the advantages and disadvantages of the innovation system of pharmaceutical industry at home and abroad,and puts forward some suggestions on establishing and perfecting the innovation system of pharmaceutical industry in China according to the development situation of foreign pharmaceutical industry.

关 键 词：医药产业 创新体系 药物研发 

分 类 号：F416.72[经济管理—产业经济]